THE US Food and Drug Administration has approved Odactra, a new "allergen extract" to treat house dust mite-induced nasal and eye inflammation.
Odactra is administered sublingually and exposes patients to house dust mite allergens, gradually training the immune system in order to reduce the severity of allergic reactions.
The first dose of the once daily tablet must be taken under the supervision of a health professional with experience in allergic diseases.
The above article was sent to subscribers in Pharmacy Daily's issue from 03 Mar 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Mar 17
